Research Papers:

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells

Claudia C. Roskopf _, Todd A. Braciak, Nadja C. Fenn, Sebastian Kobold, Georg H. Fey, Karl-Peter Hopfner and Fuat S. Oduncu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:22579-22589. https://doi.org/10.18632/oncotarget.8022

Metrics: PDF 2176 views  |   HTML 2463 views  |   ?  


Claudia C. Roskopf1, Todd A. Braciak1, Nadja C. Fenn2, Sebastian Kobold3, Georg H. Fey4, Karl-Peter Hopfner2, Fuat S. Oduncu1

1Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, Hematology/Oncology, Munich, Germany

2Ludwig-Maximilians-Universität München, Department of Biochemistry and Gene Center, Munich, Germany

3Center for Integrated Protein Science (CIPSM) and Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, Division of Clinical Pharmacology, Munich, Germany

4Friedrich-Alexander-University Erlangen-Nuremberg, Department of Biology, Erlangen, Germany

Correspondence to:

Claudia C. Roskopf, e-mail: [email protected]

Keywords: leukemia, mixed phenotype acute leukemia (MPAL), immunotherapy, dual-targeting triplebody, selectivity

Received: November 11, 2015     Accepted: February 23, 2016     Published: March 10, 2016


Simultaneous targeting of multiple tumor-associated antigens (TAAs) in cancer immunotherapy is presumed to enhance tumor cell selectivity and to reduce immune escape.

The combination of B lymphoid marker CD19 and myeloid marker CD33 is exclusively present on biphenotypic B/myeloid leukemia cells. Triplebody 33-3-19 binds specifically to both of these TAAs and activates T cells as immune effectors. Thereby it induces specific lysis of established myeloid (MOLM13, THP-1) and B-lymphoid cell lines (BV173, SEM, Raji, ARH77) as well as of primary patient cells. EC50 values range from 3 pM to 2.4 nM. In accordance with our hypothesis, 33-3-19 is able to induce preferential lysis of double- rather than single-positive leukemia cells in a target cell mixture: CD19/CD33 double-positive BV173 cells were eliminated to a significantly greater extent than CD19 single-positive SEM cells (36.6% vs. 20.9% in 3 hours, p = 0.0048) in the presence of both cell lines. In contrast, equivalent elimination efficiencies were observed for both cell lines, when control triplebody 19-3-19 or a mixture of the bispecific single chain variable fragments 19-3 and 33-3 were used. This result highlights the potential of dual-targeting agents for efficient and selective immune-intervention in leukemia patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8022